Meeting
2011 ASCO Annual Meeting
A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer.
Authors
W. K. Oh
Mount Sinai Medical Center, New York, NY
W. K. Oh , M. D. Galsky , M. Barry , F. Fennessey , J. P. Richie , J. H. Hayes , R. S. Bhatt , M. Taplin , P. G. Febbo , R. W. Ross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00321646
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4642)
Abstract #
4642
Poster Bd #
10B
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).
First Author: Rana R. McKay
Poster
2024 ASCO Annual Meeting
Clinical characteristics and treatment patterns of patients with high-risk localized prostate cancer (HR LPC) treated with radical prostatectomy (RP) and perioperative hormonal therapy (HT) in Japan, South Korea, and Taiwan.
First Author: Shingo Hatakeyama
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2023 ASCO Genitourinary Cancers Symposium
A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
First Author: Karan Jatwani